There is growing evidence that slight increases in urinary albumin excretion. below the levels normally detected by semi-quantitative reagent strips, are predictive of clinical nephropathy developing in diabetic subjects. I It has also been shown that stricter glycaemic control, particularly in insulin-dependent diabetics, can reverse this microalbuminuria and hence delay development of this nephropathy. 2 The rapid and accurate measurement of such subclinical increases in urinary albumin is therefore of some importance. We describe here a modification of a previously reported enzyme-linked immunosorbent assay' which is ideally suited for studies in large diabetic populations.
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Materials and methods

Antisera
Rabbit anti-human albumin (I st antibody) was obtained from Dako Ltd. High Wycombe. Bucks, UK; goat anti-human albumin (2nd antibody) from Miles Laboratories Ltd, Slough, UK; and rabbit anti-goat IgG linked to horse radish peroxidase (antibody-enzyme) from Miles Laboratories Ltd. Slough, UK.
Buffers, diluent and wash solutions
(a) Coating buffer: sodium carbonate (O·OIS mmol/L) and sodium bicarbonate (O·03S mmoll L). pH 9·6.
(b) Diluent solution: phosphate buffered saline containing Tween 20 (II·S milL, Sigma Chemical Co., Poole. Dorset, UK), pH 7·4.
(c) Wash solution: phosphate buffered saline containing Tween 20 «(J·I ml/l., Sigma), pH 7·4.
(d) Chromogen buffer: o-phenylenediamine (0,5 g/L. Sigma) was added to a solution of disodium hydrogen phosphate (22·5 g/L) and citric acid (5,6 g/L). pH 6·0. This solution was stored in 21l mL portions at -20°C. For use, 20 mL portions were thawed and O·1l1 mL of H 202 (30'Y" w/v) was added.
Standards
Standards were prepared from a stock standard solution of human albumin (Sigma, Cohn fraction V) in diluent solution. This solution contained 200 mglL of albumin and was stored frozen at -20°C in I mL portions. Working standards covering the range 2-IO()() J.lglL were made up from dilutions of the stock standard before each assay.
Assay procedure
Polyvinyl rnicrotitre plates (M29. Dynatech Laboratories, Billingshurst, Sussex, UK) were coated with 1st antibody by adding 0·1 mL of the diluted antibody (I: 10 O()() in coating buffer) to each well. Plates were covered and incubated at room temperature. After at least I h 30 min they were emptied and washed four times with wash solution. leaving 1 min between each wash. A volume of 0·1 mL of blank, standard or test urine (diluted 1:\110 in diluent solution) was then added to duplicate wells at timed intervals. Plates were again covered and left to incubate at room temperature for 40 min before being aspirated and washed as before. Second antibody (0' J ml., diluted 1:10 000 in diluent solution) was then added to each well. After incubation for a further 40 min, the plates were aspirated and washed as before. Antibody-enzyme (0,1 ml., diluted] :5000 in diluent solution) was added to each well and after a further incubation (20 min) the plates were aspirated and washed four times. Freshly prepared chromogen buffer (0,1 mL) was then added and the plates covered and left in the dark for 15 min. The reaction was stopped by the addition of H 2S04 (0,1 ml., 4 moI/L).
Absorbances were measured at 490 nm using a micro-elisa reader (Vitatron UK, Maidenhead, Berks, UK). The standard results were used to construct a curve against which patients and controls were read. Accepted for publication 26 September J986
and could allow reporting of results. if necessary. before the patient leaves the diabetic clinic.
Results and discussion
We have employed several minor modifications to the work of Fielding. Price and Houlton.. ' The use of polyvinyl microtitre plates with their increased binding of antibody allowed us to reduce reagent and sample volumes as well as incubation times. I n addition. the decreased antibody-enzyme dilution and its shorter incubation time reduced the non-specific binding of label. A typical standard curve is shown in Fig. I . The assay sensitivity allowed ready distinction of the lowest standard (2·0~lglL) from zero (equivalent to 0·2 mglL in urines diluted I: 11K).
Within-batch precision of the assay. as assessed by estimating the albumin in two separate patient samples. was R·6'X. at III·S ug/l, (11=26) and 5·4% at 363 ltgiL (n=22). The between-batch precision. using two further urine samples stored at -20°C until use. was 7.5°;', at 96~glL (11=12) and H·2% at 440 ug/L (11=14).
Measurement before and after the addition of the equivalent of 50 and 400~glL of albumin to urine gave analytical recoveries of III % and J02'}'0 respectively. Urine samples were collected over a 3 h period from each of 12 healthy. fasting individuals and the albumin excretion rate was determined for each. The range obtained was 0·5-10·4 ug/min (concentration range O·4-C}·5 mglL).
In similar collections from selected type II diabetic subjects (16 men. 34 women) the excretion rate ranged from 0·2 to 315~glmin (concentration range ()·2-200 mg/L). Both these sets of results are in close agreement with previously published data on healthy and type II diabetic subjects. H This enzyme immunoassay is easy to set up and rapid to perform. making use of antisera and conjugates currently available in the UK. The 1st antibody incubation may be carried out overnight at room temperature. thus cutting down the assay time. on the day. to around 2 h. This does not result in any loss of assay quality
